Candel Therapeutics, Inc.

NASDAQ•CADL

CEO: Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

セクター: Healthcare

業種: Biotechnology

上場日: 2021-07-27

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

連絡先情報

117 Kendrick Street, Suite 450, Needham, MA, 02494, United States

617-916-5445

www.candeltx.com

時価総額

$279.99M

PER (TTM)

-7.3

19.2

配当利回り

52週高値

$7.25

52週安値

$4.34

52週レンジ

26%

順位58Top 85.6%

2.3

F-Score

改良版 Piotroski 分析

6年ファンダメンタル

弱い • 2.3 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2020-2025

財務ダッシュボード

Q4 2025 データ

売上高

$0.00+0.00%

直近4四半期の推移

EPS

-$0.54+0.00%

直近4四半期の推移

フリーCF

-$10.98M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Net Loss Narrows Significantly Net loss decreased $16,995 K to $(38,182) K for 2025, reflecting reduced warrant liability impact.

Aglatimagene Prostate Success Phase 3 DFS endpoint met for aglatimagene plus radiation (HR 0.70); median DFS not reached.

R&D Investment Increases Research and development expenses increased $11.18M to $30.50M, driven by clinical trial manufacturing costs.

Cash Position Strengthened Cash and equivalents totaled $119.73M by year-end 2025, supported by recent financing activities.

リスク要因

Substantial Funding Required Need substantial additional funding; inability to raise capital forces program delays, reductions, or cessation of operations.

No Product Sales Revenue Limited operating history; no revenue generated from product sales; expecting continued operating losses for foreseeable future.

Clinical Trial Success Dependency Business success depends on clinical trials adequately demonstrating safety and efficacy for aglatimagene and linoserpaturev.

Unpredictable Regulatory Approval Regulatory approval processes are lengthy, complex, and inherently unpredictable, potentially impairing revenue generation.

見通し

Prostate BLA Submission Planned Ongoing dialogue with FDA for aglatimagene BLA submission in prostate cancer targeted for fourth quarter of 2026.

NSCLC Phase 3 Trial Launch Plan to initiate pivotal phase 3 trial for metastatic NSCLC patients resistant to ICI treatment in second quarter of 2026.

Cash Runway Extended Existing cash plus 2026 Follow-On Offering proceeds expected to fund operations into the first quarter of 2028.

Biomarker Data Presentation Expect to present novel immunological biomarker data in localized prostate cancer patients during third quarter of 2026.

同業比較

売上高 (TTM)

EDIT

$40.52M

+25.4%

PRQR

$17.94M

-15.9%

IMMP

$8.35M

+121.2%

粗利益率 (最新四半期)

EDIT

100.0%

+2621.3pp

ACIU

100.0%

+0.0pp

PRQR

85.5%

+0.0pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CAPR	$1.59B	-16.1	-67.5%	5.9%
DRTS	$689.12M	-15.7	-57.3%	12.9%
CTNM	$484.25M	-6.7	-30.1%	3.0%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

N/M

売上高の変動が大きい

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月7日

EPS:-$0.31

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし